Ali Tabatabaii Aliasghar Ahmadraji Alireza Khodabande Mohammadreza Mansouri
10.4103/0974-9233.106402
Middle East Afr J Ophthalmol
2013 Jan-Mar;20(1):87-8.
bevacizumab endophthalmitis intravitreal injection
CC BY-NC-SA
https://pubmed.ncbi.nlm.nih.gov/23580860/
Angiogenesis Inhibitors / adverse effects Antibodies, Monoclonal, Humanized / adverse effects Endophthalmitis / etiology Eye Infections, Bacterial / etiology Staphylococcal Infections / etiology
Angiogenesis Inhibitors / adverse effects Antibodies, Monoclonal, Humanized / adverse effects Endophthalmitis / etiology Eye Infections, Bacterial / etiology Staphylococcal Infections / etiology Case Reports Acute Disease Aged Anti-Bacterial Agents / therapeutic use Bevacizumab Ceftazidime / therapeutic use Drug Therapy, Combination Endophthalmitis / diagnosis Endophthalmitis / drug therapy Eye Infections, Bacterial / diagnosis Eye Infections, Bacterial / drug therapy Female Humans Intravitreal Injections Middle Aged Staphylococcal Infections / diagnosis Staphylococcal Infections / drug therapy Staphylococcus epidermidis / isolation & purification Vancomycin / therapeutic use Vascular Endothelial Growth Factor A / antagonists & inhibitors Vitrectomy Vitreous Body / microbiology Angiogenesis Inhibitors Anti-Bacterial Agents Antibodies, Monoclonal, Humanized VEGFA protein, human Vascular Endothelial Growth Factor A Bevacizumab Vancomycin Ceftazidime
PMC3617537
23580860
Acute bilateral endophthalmitis following bilateral intravitreal bevacizumab (avastin) injection
2013